Animal StudyHighlighted
MHID-5014710PMID: 407174652025British Journal of Pharmacology
Shuqi Meng, Jianfeng Liu, Yanhua Luo, Yan Fan, Zhiwei Wang, Yu Song, et al.
Background and Purpose: Sepsis-induced cardiomyopathy (SIC) is the primary cause of mortality among people with sepsis. Hydrogen (H2) has a cardioprotective effect in SIC; however, its specific mechanism remains unclear. We thus explored whether 2% H2 treatment mitigates SIC through inhibiting Golgi stress and investigated the specific molecular pathways underlying this protective effect.
Experime
Animal Study
MHID-5679511PMID: 383958002024BMC Anesthesiology
Yan Cui, Yingning Li, Shuqi Meng, Yu Song, Keliang Xie
Background: Approximately 40 to 60% of patients with sepsis develop sepsis-induced cardiomyopathy (SIC), which is associated with a substantial increase in mortality. We have found that molecular hydrogen (H2) inhalation improved the survival rate and cardiac injury in septic mice. However, the mechanism remains unclear. This study aimed to explore the regulatory mechanism by which hydrogen modula
Clinical TrialHighlighted
MHID-1947207PMID: 346511332021Critical Care Explorations
Alexis R. Cole, BS, Francesca Sperotto, MD, James A. DiNardo, MD, Stephanie Carlisle, Michael J. Rivkin, MD, Lynn A. Sleeper, ScD, et al.
BACKGROUND: Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled hydrogen gas at doses required for a clinical efficacy study.
DESIGN: Prospective, single-arm study.
SETTING: T
